Body mass index is prognostic in metastatic colorectal cancer: Pooled analysis of patients from first-line clinical trials in the ARCAD database Review uri icon

Overview

MeSH Major

  • Body Mass Index
  • Cachexia
  • Colorectal Neoplasms

abstract

  • Low BMI is associated with an increased risk of progression and death among the patients enrolled on the mCRC trials, with no increased risk for elevated BMI, in contrast to the adjuvant setting. Possible explanations include negative effects related to cancer cachexia in patients with low BMI, increased drug delivery or selection bias in patients with high BMI, and potential for an interaction between BMI and molecular signaling pathways.

publication date

  • January 10, 2016

Research

keywords

  • Review

Identity

Language

  • eng

PubMed Central ID

  • PMC5070548

Digital Object Identifier (DOI)

  • 10.1200/JCO.2015.61.6441

PubMed ID

  • 26503203

Additional Document Info

start page

  • 144

end page

  • 50

volume

  • 34

number

  • 2